Insulet $PODD tumbles 12.1% after cutting FY revenue outlook

Insulet $PODD fell 12.1% pre-market after the company beat second-quarter earnings expectations but slashed its full-year revenue growth forecast. The move came after management pointed to softer U.S. Omnipod growth in the back half of 2026, a combination that is pressuring sentiment heading into today’s session.

What Happened

Insulet reported adjusted earnings of $1.66 per share, ahead of the $1.45 consensus estimate, while revenue rose 23.5% year over year to $801.7 million, also topping expectations. Despite that headline beat, the stock sold off sharply after the company narrowed its fiscal 2026 revenue growth outlook to 20% to 22% from 21% to 23% and cut its U.S. Omnipod growth target to 17% to 19% from 20% to 22%.

The guide-down was the key issue for traders. Insulet also forecast third-quarter revenue of about $829.9 million to $844.0 million, which came in below the Street’s $845.5 million estimate. Management said the revised outlook reflects a softer second half, particularly in U.S. Omnipod sales.

International growth was a bright spot: Insulet raised its overseas Omnipod forecast to 30% to 32% from 26% to 28%. Still, the market focused on the slower domestic trajectory, since U.S. demand is the bigger driver of the company’s near-term narrative.

Analyst Take

This is a classic “beat-and-cut” reaction: strong reported numbers, weaker forward expectations. For active investors, the issue is not whether Insulet is still growing — it is — but whether the growth rate is decelerating faster than the market had priced in.

The guidance reduction matters more than the earnings beat because it signals potential demand headwinds in the diabetes device market, especially in the U.S. Omnipod franchise. That raises the bar for the stock, which had been supported by expectations for durable high-20s growth and continued expansion into type 2 diabetes.

Insulet’s revised outlook may still imply solid growth by large-cap medtech standards, but guidance is what sets the next leg of the stock. When forward revenue comes in below estimates, shares often re-rate quickly even if the quarter itself looks clean.

What to Watch

Whether management gives a clearer explanation for the softer U.S. Omnipod trend and whether it is tied to retention, utilization, or broader market demand.
How the third-quarter guide compares with expectations once investors digest the full details of the call and any updated commentary on type 2 diabetes adoption.
Whether international momentum can offset slower U.S. growth enough to stabilize the full-year story.
Price action around the open: after a double-digit pre-market drop, traders will watch for capitulation, stabilization, or further downside if guidance concerns dominate.

Insulet $PODD tumbles 12.1% after cutting FY revenue outlook